Sharechat Logo

AFT to announce full year results on May 23 2024

Friday 3rd May 2024

Text too small?

AFT Pharmaceuticals to announce full year results on Thursday May 23 2024

 

AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announced today that it intends to release its full year FY2024, ended March 31 2024, results on Thursday May 23 2024. The release will be issued at around 09:00 am (NZT) on the NZX and ASX.

 

Following the release, management will present via webinar at 10:30 am (NZT). Presentation material will be available on the company’s website AFT, the NZX website NZX and the ASX website ASX.

 

To participate in the upcoming earnings webinar, please pre-register with the provided link, below. Webinar details will be provided upon completion of your registration.

 

Registration Link: AFT results presentation FY2024

 

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.

 

For more information:

 

Investors Media

Malcolm Tubby Richard Inder

CFO, AFT Pharmaceuticals Ltd The Project

Phone: +64 9 488 0232 Phone: 021 645 643

Email: malcolm@aftpharm.com Email: richard@theproject.co.nz

 

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com

 AFT Pharmaceuticals to announce full year results on Thursday May 23 2024



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 5th Morning Report
Kiwi Property launches Green Bond offer
TEM - Transaction in Own Shares
December 2nd Morning Report
MWE - Intention to De-list from the NZX Main Board
KMD Brands announces Release of Climate-Related Disclosure
Rua Bioscience expands product range in New Zealand
SPG - HY25 Interim Results
PaySauce FY25 Half Year Result and Interim Report
Synlait releases Integrated Climate Report